 |
INTRODUCTION |
Male meiosis is a process in which a dyploid spermatocyte gives
rise to four haploid round spermatids after a single round of DNA
replication followed by two subsequent cell divisions. The homologous
chromosomes are segregated in the two daughter cells (secondary
spermatocytes) during the first meiotic division, whereas the sister
chromatids, through a process resembling mitosis, are segregated during
the second division to generate haploid cells. The prophase of male
first meiotic division is a lengthy process which ensures the correct
pairing and the crossing over between homologous chromosomes. In the
mouse, this process lasts approximately 10 days, during which the
homologous chromosomes become partially condensed, anneal to each
other, and are maintained in proximity by a structure called the
synaptonemal complex. After genetic exchange (crossing over) has
occurred, the synaptonemal complex disappears and chromosome
condensation allows the sites of DNA exchange to become visible as
chiasmata. As for mitotic division, the nuclear envelope breaks down
and microtubules are assembled into a spindle. The chromosomes become
aligned to the equator of the meiotic spindle and the two sets of
homologous chromosomes are separated during the anaphase. While the
meiotic prophase is considerably long, metaphase and anaphase
transitions are rather short. Due to the difficulty of isolating
homogenous populations of synchronized cells, and the length of meiosis
I in spermatocytes, not much is known about the molecular mechanisms controlling the different steps of mammalian male meiosis (for review,
see Ref. 1).
Most of the information about cell cycle regulation during meiosis in
metazoan cells has been obtained using Xenopus
laevis oocytes naturally arrested in late G2 of
the first meiotic division. Induction of G2/M progression
by progesterone requires the expression of the proto-oncogene
mos (2-4), activation of the mitogen-activated protein
kinase (MAPK)1 cascade, and
finally activation of the cyclin B·cdc2 complex, also known as
mitosis-promoting factor, or maturation-promoting factor (MPF, for
review, see Ref. 5). Microinjection of antibodies blocking MAPK kinase
are able to block MAPK activation triggered by activated Mos, and to
block Xenopus oocyte maturation (6) and Mos cytostatic
activity at metaphase (7). Furthermore, a dominant negative p42
extracellular signal-regulated kinase 2 (ERK2) is able to block
Mos-induced MPF activation in Xenopus oocyte extracts (8).
Finally, it has been reported that activation of MPF and meiotic
progression by progesterone could be bypassed by injection of
constitutively active forms of MAPKs (9-10). Although these
observations strongly suggest a role for MAPKs in meiotic progression
and regulation of MPF activity in Xenopus oocytes, the
mechanism of this regulation is still unknown. The activity of MPF is
regulated at multiple steps, such as cyclin B synthesis, phosphorylation/dephosphorylation events (11, 12), and nuclear export
(13, 14). During G2, the cyclin B·cdc2 complex
accumulates in the oocyte, but it is kept inactive through
phosphorylation of Thr14 and/or Tyr15 by the
wee1 kinase(s). Inactivation of wee1 kinases and/or activation of the
activating phosphatase cdc25 trigger dephosphorylation of
Thr14 and Tyr15 and cause activation of MPF
(11, 15). Recently, a possible link between activation of MAPKs and MPF
has been proposed on the base of the finding that MAPK-activated
p90rsk binds to and phosphorylates the wee1 homologue Myt1
(16). This phosphorylation inhibits Myt1 activity and interferes with
inhibition of MPF activity in vitro.
In the mouse oocytes, meiotic resumption is under the negative control
of cAMP (1). When cAMP levels drop there is an increase in the activity
of MPF and MAPKs resulting in the germinal vesicle breakdown and
progression through the first meiotic division. On the contrary of what
has been observed in Xenopus oocyte maturation, activity of
Mos is dispensable for the G2/M transition after prophase I
in both female and male mice (17, 18), even though Mos might participate in some aspects of meiotic maturation in mouse oocytes (19,
20). The oocyte proceeds to the second meiotic division and arrests at
metaphase II with the sister chromatids aligned on the spindle, due to
the concerted action of Mos and MAPKs, which, at this stage, prevent
cyclin destruction and consequent MPF inactivation (5). Indeed,
Mos-knock out animals showed lack of MII arrest and high rate of
parthenogenetic activation of ovulated oocytes (17, 18).
A similar synchronization of events can be artificially reproduced in
mouse spermatocytes by treatment with the serine/threonine phosphatase
inhibitor okadaic acid (OA) (21-23). OA overcomes the checkpoints that
normally delay the progression of the meiotic cycle of mid- and late
pachytene spermatocytes and induces nuclear envelope breakdown and
chromosome condensation resembling that observed during
G2/M transition after prophase I. The meiotic progression
of mouse spermatocytes induced by OA is accompanied by an increase in
H1 kinase activity, which is considered a sign of MPF activation (22).
The increase in H1 kinase activity during OA-induced G2/M
transition in mouse spermatocytes is due to a concurrent activation of
a cyclin/cdk activity detectable in precipitates using
p13suc1-conjugated agarose (23), suggesting that activation of
MPF actually occurs under these experimental conditions.
It is not known whether, in addition to MPF, Mos and MAPKs are also
required for G2/M progression during meiosis in mouse spermatocytes. Targeted gene disruption of Mos did not produce a clear
phenotype in the male mice, and did not result in sterile animals.
However, it cannot be ruled out that, in the absence of Mos, redundant
mechanisms of MAPK activation, e.g. via Raf-1 and/or MEKKs
(24), substitute for its function. In this study we have examined the
activity of MPF and MAPKs during meiotic progression artificially
induced in mouse spermatocytes by OA treatment. We found that OA
induces a sustained activation of both MAPKs and MPF with similar time
courses. OA induces phosphorylation and activation of p44/ERK1, but not
of p42/ERK2. Immunoprecipitated p44-ERK1 from OA-stimulated male
meiotic germ cells was able to induce MPF activation in extracts from
control spermatocytes in vitro. Preincubation of cultured
pachytene spermatocytes with PD98059 (a selective inhibitor of ERK
activating kinases MEK1/2) completely blocked the ability of OA to
induce chromosome condensation and progression to meiotic metaphases.
Our results suggest an important function for ERK1/MAPK in male mouse
meiotic progression, as also indicated by changes in its subcellular
distribution during naturally occurring G2/M transition.
 |
MATERIALS AND METHODS |
Preparation of Testicular Cells--
Testes of adult CD1 mice
(Charles River Italia) were used to prepare germ cells. After
dissection of the albuginea membrane, testes were digested for 15 min
in 0.25% (w/v) collagenase (type IX, Sigma) at room temperature under
constant shaking. Digestion was followed by two washes in minimum
essential medium (Life Technologies, Inc.), hence seminiferous tubules
were cut in pieces using a sterile blade and further digested in
minimum essential medium containing 1 mg/ml trypsin for 30 min at
30 °C. Digestion was stopped by adding 10% fetal calf serum and the
released germ cells were collected after sedimentation (10 min at room
temperature) of tissue debris. Germ cells were centrifuged for 10 min
at 1,500 rpm at 4 °C and the pellet resuspended in 20 ml of
elutriation medium (120.1 mM NaCl, 4.8 mM KCl,
25.2 mM NaHCO3, 1.2 mM
KH2PO4, 1.2 mM
MgSO4(7H2O), 1.3 mM
CaCl2, 11 mM glucose, 1 × essential amino
acid (Life Technologies, Inc.), penicillin, streptomycin, 0.5% bovine
serum albumin). Germ cells at pachytene spermatocyte, round spermatid,
and elongated spermatid steps were obtained by elutriation of the
unfractionated single cell suspension as described previously (25).
Homogeneity of cell populations ranged between 80 and 85% (pachytene
spermatocytes) and 95% (round spermatids), and was routinely monitored
morphologically. Mature spermatozoa were obtained from mature mice as
described previously (26). Spermatogonia (27) and Sertoli cells (27, 28) were obtained from prepuberal mice as previously described.
Cell Culture and Treatments--
After the elutriation,
pachytene spermatocytes were cultured in minimum essential medium,
supplemented with 0.5% bovine serum albumin, 1 mM sodium
pyruvate, 2 mM sodium lactate, in 6-well dishes at a
density of 106 cells/ml at 32 °C in a humified
atmosphere containing 95% air and 5% CO2. After 12 h, cells were treated with 0.5 µM OA, or 5 µM OA, or equal volumes of the solvent dimethyl
sulfoxide, and culture was continued for up to 6 h. For time
course experiments, aliquots were taken at different time points and
processed as described below. In order to test the effect of inhibition
of ERK-activating kinases, before OA treatments, cells were
preincubated for 12 h with the specific inhibitor of MEK1/2
kinases PD98059 (Calbiochem, catalog number 513000) at the
concentration of 50 µM, or equal volumes of the solvent
dimethyl sulfoxide. For cytological and immunofluorescence analyses,
and kinase assays, aliquots of the same samples were taken and
processed accordingly.
Staining of Spermatocyte Nuclei with Giemsa--
106
cells were collected by centrifugation at 1,000 × g
for 15 min at 4 °C, pellets were resuspended in 4 ml of KCl, 75 mM hypotonic solution and incubated for 15-20 min at
37 °C. Cell lysates were fixed by adding 0.5 ml of methanol:acetic
acid solution (3:1) and incubated at 4 °C for 1 h. After a
10-min centrifugation at 1,000 × g, pellets were
washed 4 times with 4 ml of methanol:acetic acid solution (3:1), with a
10-min incubation at room temperature between each wash. After the last
wash, pellets were resuspended in 200-500 µl of methanol:acetic acid
solution (3:1) and the solution was dropped from 10 to 15 cm onto glass
slides to allow spreading of the nuclei. Slides were stained in 5%
Giemsa dye dissolved in 0.15 mM
NaH2PO4 containing 3% methanol. Slides were
washed with 0.15 mM NaH2PO4
containing 3% methanol, allowed to dry and mounted with coverslide.
Nuclei were observed by light microscopy.
Immunofluorescence Analysis--
Control or OA-treated
spermatocytes were spotted on poly-L-lysine-coated glass
slides and fixed at room temperature for 15 min in PBS containing 4%
paraformaldheyde. Cells were then permeabilized for 5 min in PBS
containing 0.1% Triton X-100 and incubated for 30 min at room
temperature with 1% fetal calf serum in PBS. After 3 washes in PBS,
cells were incubated for 1 h at 37 °C with rabbit polyclonal
anti-ERK1 (Santa Cruz Biotechnology, catalog number sc-93-G) and mouse
monoclonal anti-
-tubulin (Sigma, catalog number T4026), both at a
final concentration of 1 µg/ml, as primary antibodies. Following 5 washes (10 min in PBS), cells were incubated for 1 h at 37 °C
with cyanin 3-conjugated anti-rabbit IgGs (Chemicon, catalog number
AP132C, 1:400 dilution) and fluoresceinated anti-mouse IgGs (Sigma,
catalog number T4026, 1:200 dilution) as secondary antibodies. To stain
DNA, 0.1 mg/ml Hoechst dye (Sigma) was added to the solutions
containing the secondary antibodies. Control experiments were performed
using either rabbit or mouse non-immune IgGs in the first incubation,
or the secondary antibodies alone. After 5 more washes in PBS, slides
were mounted in 50% glycerol in PBS and immediately examined by
fluorescence microscopy.
H1 Kinase Assay--
Approximately 2 × 105
cells were collected by centrifugation at 2,000 × g
for 10 min, resuspended in 10 µl of storage solution (10 mM
p-nitrophenyl phosphate, 20 mM
-glycerophosphate, 0.1 mM sodium orthovanadate, 5 mM EGTA, 10 µg/ml leupeptin, and 10 µg/ml aprotinin)
and immediately frozen at
80 °C. Before the assay, cells were
thawed on ice and lysed for 10 min on ice in 50 µl of hypotonic H1
kinase buffer (25 mM Mops, pH 7.5, 60 mM
-glycerophosphate, 15 mM EGTA, 15 mM
MgCl2, 0.1 mM sodium orthovanadate, 1 mM dithiothreitol, 10 µg/ml leupeptin, and 10 µg/ml
aprotinin). Cell extracts were centrifuged for 10 min at 10,000 × g at 4 °C, and soluble extracts were collected and used
for H1 kinase assays. Kinase reactions using 10-15 µl of soluble
extracts were carried out for 60 min at 30 °C in a total volume of
25 µl in H1 kinase buffer containing 100 µg/ml H1 (type III-S;
Sigma), 1 µg/ml cAMP-dependent protein kinase inhibitor
(Sigma), and 0.3 mM [
-32P]ATP (0.1 µCi/µl). Reactions were stopped spotting 20 µl onto P81 paper
squares (Whatman) and immediately immersing them into 0.1% phosphoric
acid. Paper squares were washed 5 times for 10 min and air dried.
Radioactivity incorporated into H1 was determined by scintillation
counting. Values were normalized for protein content, determined
according to Bradford (29).
Myelin Basic Protein (MBP) Kinase Assay--
Samples were
collected and frozen as described for the H1 kinase assay. Cells were
thawed on ice and lysed for 10 min on ice in 50 µl of MBP kinase
buffer (20 mM Hepes, pH 7.4, 20 mM
-glycerophosphate, 1 mM dithiothreitol, 0.1 mM sodium orthovanadate, 2 mM EGTA, 20 mM MgCl2, 5 µg/ml leupeptin, 5 µg/ml
aprotinin). Reactions were carried out for 30 min at 30 °C in 25 µl of MBP kinase buffer containing 0.3 mM
[
-32P]ATP (0.2 µCi/µl) (Amersham Pharmacia
Biotech) and 0.5 mM MBP-derived peptide (Santa Cruz
Biotechnology, catalog number sc-3011) as a specific substrate for
MAPKs. Reactions were stopped by adding 1 volume of 20%
trichloroacetic acid, and proteins were allowed to precipitate on ice
for 10 min using 2 mg/ml bovine serum albumin as carrier. After
centrifugation at 8,000 × g for 10 min, aliquots of
the supernatant fractions were spotted onto P81 phosphocellulose paper
and processed as described for the H1 kinase assay (26).
Immunoprecipitation and Immunokinase Assays--
Control or
OA-treated spermatocytes (approximately 2 × 106
cell/sample) were collected by centrifugation at 2,000 × g for 10 min, and washed twice in ice-cold PBS. Cells were
homogenized in either H1 kinase buffer or MBP kinase buffer and
cytosolic fractions were collected after centrifugation at 10,000 × g for 10 min at 4 °C. For immunoprecipitation, 1 µg
of mouse monoclonal anti-cyclin B1 antibody (Santa Cruz Biotechnology,
catalog number sc-245) or rabbit polyclonal anti-ERK1 (Santa Cruz
Biotechnology, catalog number sc-93-G) or anti-ERK2 antibody (Santa
Cruz Biotechnology, catalog number sc-154-G) were preincubated for 60 min with a mixture of protein A- and protein G-Sepharose beads (Sigma)
under constant shaking at 4 °C. At the end of the incubation, the
beads were washed once with 20 mM Tris-HCl, pH 7.8, containing 0.5 M NaCl, twice with 20 mM
Tris-HCl, pH 7.8, and then incubated for 90 min at 4 °C with the
soluble spermatocyte cell extracts (0.5 mg of protein) under constant
shaking. Sepharose bead-bound immunocomplexes were rinsed three times
with PBS containing 0.05% bovine serum albumin, and twice with either
H1 kinase buffer or MBP kinase buffer. Anti-cyclin B1 pellets were then
incubated with 1 µg of H1, 1 µg of cAMP-dependent
protein kinase inhibitor, and 0.3 mM [
-32P]ATP (0.1 µCi/µl) in H1 kinase buffer (total
volume 30 µl) for 30 min at 30 °C. Anti-ERKs pellets were
incubated with either 0.5 mM MBP-derived peptide or 1 µg
of full-length MBP (Sigma, catalog number M1891) and 0.3 mM
[
-32P]ATP (0.1 µCi/µl) in MBP kinase buffer (total
volume 30 µl) for 30 min at 30 °C. Samples incubated with the
MBP-derived peptide were processed as described in the paragraph
describing the MBP kinase assay. As for the samples incubated with H1
or with the full-length MBP protein, at the end of the incubation,
pellets were separated by centrifugation (3,000 × g
for 5 min) and the supernatants were diluted in SDS-PAGE sample buffer
(62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 2% (w/v) SDS,
0.7 M 2-mercaptoethanol, and 0.0025% (w/v) bromphenol
blue). Radioactivity incorporated into H1 or MBP was analyzed by
autoradiography after separation of the proteins on SDS-PAGE gel. In
some experiments, immunoprecipitation pellets were washed two
additional times with PBS, immunocomplexes were then eluted in SDS-PAGE
sample buffer for Western blot analysis.
Kinase Assays in MBP-containing SDS-PAGE Gels--
Control or
OA-treated spermatocytes were collected as described above for MBP
kinase assays. Soluble extracts were diluted in SDS-PAGE sample buffer
and separated on polyacrylamide gels containing 0.1 mg/ml full-length
MBP. After the run, SDS was removed by washing the gel twice in 20%
2-propanol in 50 mM Tris-HCl, pH 8.0, for 1 h at room
temperature. Proteins were then denatured by incubation of the gel in 6 M guanidine HCl at room temperature for 1 h, and
renatured overnight with five washes in 50 mM Tris-HCl, pH
8.0, containing 0.04% Tween 20 and 5 mM 2-mercaptoethanol. The gel was then preincubated for 1 h at 25 °C in 50 mM Hepes, pH 8.0, containing 2 mM
dithiothreitol and 10 mM MgCl2. Phosphorylation of MBP was carried on for 1 h at 25 °C in 10 ml of
preincubation buffer adding 0.5 mM EGTA, 2 µM
cAMP-dependent protein kinase inhibitor, 40 µM ATP, and 100 µCi of [
-32P]ATP. The
reaction was stopped by immersing the gel in 5% trichloroacetic acid
solution containing 10 mM sodium pyrophosphate. The gel was washed for 5-10 times in the same solution, dried, and subjected to autoradiography.
Activation of MPF by Immunoprecipitated Activated
ERK1--
Spermatocyte cell extracts from control or OA-treated cells
were immunoprecipitated with either anti-ERK1 antibody or anti-ERK2 antibody essentially as described for the MBP-immunokinase assay. After
the washes with MBP kinase buffer, immunocomplexes were incubated for
30 min with a soluble cell extracts from untreated spermatocytes
(approximately 0.2 mg/sample) at 30 °C under constant shaking. At
the end of the incubation, soluble cell extracts and immunocomplexes
were separated by centrifugation at 3,000 × g for 5 min, and H1 kinase activity was measured in the supernatant fractions
as described above.
Western Blot Analyses--
Spermatocyte cell extracts were
separated on 10% SDS-PAGE, transferred onto nitrocellulose membrane
(Amersham Pharmacia Biotech) and subjected to Western blot analysis
with anti-ERK1 (100 ng/ml) (Santa Cruz Biotechnology, catalog number
sc-93-G), anti-ERK2 (100 ng/ml) (Santa Cruz Biotechnology, catalog
number sc-154-G), or PanERK (300 ng/ml) (Transduction Laboratories,
catalog number E17120) rabbit polyclonal antibodies, or the mouse
monoclonal antibody anti-p-ERK (400 ng/ml) (Santa Cruz Biotechnology,
sc-7383). The first antibody incubation was carried on for 90 min at
room temperature. Second antibody incubation was carried out with
either 1:10,000 dilution of anti-rabbit-IgGs antibody, or with 1:5,000 dilution of anti-mouse IgGs antibody conjugated to horseradish peroxidase (Amersham Pharmacia Biotech). Immunostained bands were detected by the ECL chemiluminescent method (Amersham Pharmacia Biotech). The anti-p-ERK monoclonal antibody specifically recognizes tyrosine-phosphorylated active ERKs, and we tested its specificity by
treatment of cell extracts with calf intestine alkaline phosphatase, which completely suppressed recognition of the relative bands, unless
calf intestine alkaline phosphatase treatment was performed in the
presence of phosphatase inhibitors (data not shown).
 |
RESULTS |
Activation of Cyclin B1/cdc2 (MPF) during the OA-induced
G2/M Transition in Mouse Spermatocytes--
It has been
previously reported that treatment of mouse spermatocytes with the
serine/threonine phosphatase inhibitor OA, in the presence of 5% fetal
calf serum, is able to induce G2/M progression in
approximately 90% of the cells within 4-6 h (21, 22). OA triggered
nuclear envelope breakdown and chromosome condensation and this
phenomenon was accompanied by a 2-4-fold increase in H1 kinase
activity (22, 23), which was interpreted to reflect activation of MPF,
since it was also detected in p13suc1-agarose precipitates
(23). In our experimental conditions, treatment with 5 µM
OA in the absence of fetal calf serum induced a dramatic chromatin
condensation which was observed in about 90% of the cells (Fig.
1A, right side), suggesting
that serum is not required for G2/M transition induced by
OA treatment. Activation of H1 kinase activity was accompanied by a
rapid (2-fold activation after 1 h) and sustained increase in H1
kinase activity that reached a maximum (5-fold) between 4 and 6 h
(Fig. 1B). To investigate whether the increase in H1 kinase
activity was indeed due to activation of MPF, we immunoprecipitated MPF
activity from control and treated cells using a monoclonal antibody
that recognizes cyclin B1 (see "Materials and Methods"), the major
cyclin component of MPF in these cells (30). Immunoprecipitates from
control and OA-treated cells were incubated with purified H1 and
[
-32P]ATP, and the soluble fractions were then
analyzed by SDS-PAGE and autoradiography for phosphorylation of the H1
substrate (Fig. 1C). Densitometric analysis indicates that
4-h treatment of spermatocytes with OA induced a 4-fold increase in
cyclin B1/cdc2 kinase activity (Fig. 1D), demonstrating that
the increase in H1 kinase activity observed in the cytosolic extracts
(Fig. 1B) is actually due to activation of MPF.

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 1.
Activation of cyclin B1/cdc2 (MPF) during the
OA-induced G2/M transition in mouse spermatocytes.
A, Giemsa staining of nuclei from control spermatocytes
(left side) and spermatocytes treated for 4 h with 5 µM OA (right side). Magnification: × 420. B, H1 kinase assay on cell extracts from middle-late
pachytene mouse spermatocytes treated with 5 µM OA for
the indicated times. C, phosphorylation of H1 by anti-cyclin
B1 immunoprecipitates from control and OA-treated spermatocytes.
Immunoprecipitated cyclin B1·cdc2 complexes from 2 × 106 cells were assayed for kinase activity using H1 as
substrate. After separation by centrifugation and several washes,
immunocomplexes were resuspended in H1 kinase reaction buffer and
incubated under constant shaking for 30 min at 30 °C. After
separation by centrifugation, the soluble fraction was analyzed by
SDS-PAGE and autoradiography. This experiment was repeated three times
with similar results. D, densitometric analysis of the bands
shown in C to evaluate the degree of H1 phosphorylation by
MPF in control and OA-treated spermatocytes.
|
|
ERK Kinases Expression in Testicular Cells--
To investigate the
role of MAPKs in the male meiosis, we analyzed the expression of ERK1
and ERK2 in germ cells and somatic cells of the testis by Western blot
analysis. Spermatogonia were isolated from 8-day-old mice, Sertoli
cells were isolated from 17-day-old mice, and spermatocytes, round and
elongated spermatids, and spermatozoa were isolated from adult mice
(see "Materials and Methods"). As shown in Fig.
2, both ERK1 and ERK2 were expressed in
all the cells examined. The anti-ERK1 antibody recognized two major
bands in cytosolic extracts, a 44-kDa band which corresponds to ERK1
and a 42-kDa band that corresponds to ERK2. Although this antibody
recognized both MAPK isoforms, it showed some specificity toward ERK1,
as shown by the staining of only the 44-kDa band in mouse spermatozoa,
where the levels of MAPKs are much lower than in the other cells. The
anti-ERK2 antibody mainly recognized the p42 ERK2 isoform, even though
a fainter band corresponding to p44 ERK1 was also detected in most
samples (Fig. 2). These data indicate that these antibodies recognize
only p44 ERK1 and p42 ERK2, although with variable degree of
cross-reactivity, and not other MAPK isoforms. They also indicate that
both ERKs are expressed in pre-meiotic, meiotic, and post-meiotic germ
cells as well as in Sertoli cells. Mature spermatozoa have lower
amounts of both MAPKs.

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 2.
ERK kinase expression in mouse testicular
cells. Immunoblot analysis of protein extracts (50 µg) from the
indicated cell types using affinity purified anti-ERK1 or anti-ERK2
polyclonal antibodies.
|
|
Activation of MAPKs during the OA-induced G2/M
Transition in Mouse Spermatocytes--
In mouse oocytes, a parallel
activation of MPF and MAPKs occurs during G2/M transition
of both meiotic divisions (31) and MAPK activation is necessary for
chromosome condensation in these cells (32). To test whether
G2/M transition induced by OA in mouse spermatocytes also
involves activation of MAPKs, we measured kinase activity in soluble
cell extracts using a peptide derived from MBP as a specific substrate
for MAPKs. OA triggered activation of MAPKs in pachytene spermatocytes
with a time course similar to that seen for MPF (Fig.
3). An increase in MAPK activity was detectable as early as 60 min after OA stimulation (75% increase) and
reached a maximum (5-fold increase) after 4 h of treatment.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 3.
Activation of MAPKs during the OA-induced
G2/M transition in mouse spermatocytes. MBP kinase
assay on cell extracts from middle-late pachytene mouse spermatocytes
treated with 5 µM OA for the indicated times, using a
MBP-derived peptide as a specific substrate for MAPKs and cell extracts
from 2 × 106 cells (see "Materials and Methods"
for details).
|
|
Specific Activation of ERK1 during the OA-induced Meiotic
G2/M Transition--
To investigate whether the increase
in MAPK activity was attributable to ERK1 and/or ERK2, MAPKs were
immunoprecipitated with either anti-ERK1 or anti-ERK2 antibodies and
MBP kinase activity of the immunoprecipitates was measured. Both
antibodies immunoprecipitated MBP kinase activity from control
spermatocytes, however, while OA induced a 2-fold activation of MBP
kinase immunoprecipitated with anti-ERK1, it induced only a small
increase in the activity precipitated with anti-ERK2 (Fig.
4A). Since the two antibodies have a certain degree of cross-reactivity between p44 ERK1 and p42 ERK2
(Fig. 2), it is likely that the small increase in activity measured in
the anti-ERK2 immunoprecipitates is due to ERK1 co-precipitating with
ERK2. On the other hand, the actual degree of specific ERK1 stimulation
might be masked by co-immunoprecipitating ERK2 in anti-ERK1
immunoprecipitates. Furthermore, when the immunoprecipitates were
incubated with the full-length MBP protein and
[
-32P]ATP, followed by SDS-PAGE and autoradiography,
we observed a more evident phosphorylation of MBP after OA treatment in
anti-ERK1 than in anti-ERK2 immunoprecipitates (Fig. 4B).
These data suggest that OA essentially induces activation of ERK1,
rather than of ERK2 in mouse spermatocytes. To test this assumption, we
utilized an in-gel kinase assay of spermatocyte extracts with the
full-length MBP protein, which is a substrate also for other protein
kinases. OA induced a large increase in MBP kinase activity of two
major polypeptide bands, of approximately 55 and 44 kDa (Fig.
5A). Control in-gel kinase
assays performed without addition of the MBP substrate showed that the
p55 and p44 bands do not represent OA-induced autophosphorylating
kinases (data not shown). Only the 44-kDa polypeptide band showed a
time course of activation comparable to the time course of MAPK
activation measured in whole cell extracts using the MBP-derived
peptide shown in Fig. 3, with a maximum of activation between 4 and
6 h. The ~55-kDa band appeared to be maximally stimulated after
just 1 h of OA treatment, suggesting that it corresponds to a
OA-activated protein kinase which phosphorylates MBP in a region
different from the fragment specifically phosphorylated by MAPKs.
Moreover, the 44-kDa band co-migrated with ERK1, as shown by parallel
Western blot analysis of spermatocyte extracts using either specific
anti-ERK1 and anti-ERK2 antibodies (Fig. 5B), or an
anti-MAPKs antibody (Pan-ERK) which recognize several other isoforms of
this family (Fig. 5C). Densitometric analysis of the 44-kDa
band detected in the MBP in-gel kinase assay shown in Fig.
5A revealed a 4-fold increase after 4 h of treatment
with OA. This degree of activation is similar to MAPK activation
measured in whole cell extracts using the MBP-derived peptide shown in Fig. 3. These results confirm that the actual increase in ERK1 activity
induced by OA treatment is higher than the 2-fold increase detected
with the immunokinase assay shown in Fig. 4, and that ERK2 is not
activated by OA treatment.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 4.
OA treatment activates ERK1 but not ERK2 in
mouse spermatocytes. A, MBP kinase assay in anti-ERK1 and
anti-ERK2 immunoprecipitates from control and OA-treated spermatocytes
(5 µM, 4 h). After ERKs were immunoprecipited from
2 × 106 cells, a kinase assay was performed using the
same MBP-derived peptide used in Fig. 3 as a specific MAPK substrate.
Data represent the mean ± S.D. of triplicate determinations from
three separate experiments. B, phosphorylation of the
full-length MBP protein by anti-ERK1 and anti-ERK2 immunoprecipitates
from control and OA-treated spermatocytes. After immunoprecipitation of
ERKs, a kinase assay was performed using the full-length MBP protein as
a substrate, and the soluble fraction was analyzed by SDS-PAGE and
autoradiography.
|
|

View larger version (70K):
[in this window]
[in a new window]
|
Fig. 5.
OA treatment activates different MBP kinases
in mouse spermatocytes, but specifically activates ERK1 and not other
MAPKs. A, kinase assay in SDS-PAGE gels containing 0.1 mg/ml
of the full-length MBP protein. Soluble extracts (50 µg) from
spermatocytes treated with 5 µM OA for the indicated
times were separated by SDS-PAGE. After removal of SDS and a cycle of
protein denaturation and renaturation, a direct in-gel kinase assays
was performed by adding [ -32P]ATP (see "Materials
and Methods" for details). This experiment was repeated four times
with similar results. B, parallel immunoblot analysis using
specific anti-ERK1 and anti-ERK2 antibodies of cell extracts (50 µg)
from spermatocytes treated for 4 h with 5 µM OA.
C, parallel immunoblot analysis using the pan-ERK antibody
of cell extracts (50 µg) from control or OA-treated
spermatocytes.
|
|
Specific Phosphorylation of ERK1 on a Tyrosine Residue Involved in
Enzyme Activation during the OA-induced Meiotic G2/M
Transition--
We also performed Western blot analysis on
spermatocyte cell extracts using a mouse monoclonal anti-phospho-ERK
(anti-p-ERK) antibody, which specifically recognizes an epitope
corresponding to amino acids 196-209 of ERK1 of human origin
phosphorylated on Tyr204 (identical to the corresponding
ERK2 sequence). This antibody specifically recognize both mouse ERK
isoforms only when they are tyrosine phosphorylated in the
corresponding mouse epitopes, which reflects the activated state of
these enzymes (33). Fig. 6 shows that OA
treatment clearly increases the phosphorylation of ERK1, but not of
ERK2, on the tyrosine residue present in the epitope recognized by this
antibody. These data confirm that OA induces activation of ERK1, rather
than of ERK2 in mouse spermatocytes.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 6.
OA treatment specifically stimulates
phosphorylation of ERK1, but not ERK2, on a tyrosine residue required
for enzyme activation. A, immunoblot analysis of protein
extracts (70 µg) from control or OA-treated (5 µM,
4 h) mouse pachytene spermatocytes using the monoclonal anti-p-ERK
antibody, which specifically recognizes an epitope corresponding to
amino acids 196-209 of ERK1 of human origin phosphorylated on
Tyr204 (identical to the corresponding ERK2 sequence, and
cross-reactive with mouse ERKs). This experiment was repeated three
times with similar results. B, the same samples shown in
A were probed with a mixture of anti-ERK1 and anti-ERK2
polyclonal antibodies to show that OA treatment does not affect the
expression levels of the two ERK isoforms.
|
|
Subcellular Redistribution of ERKs in Mouse Spermatocytes during
the G2/M Transition--
The localization of ERKs in mouse
spermatocytes was investigated by immunofluorescence analysis, using
the anti-ERK1 polyclonal antibody (Fig.
7). In untreated cells, mostly
represented by mid-late pachytene spermatocytes, and a few
contaminating round spermatids, anti-ERK1 immunostaining was uniformely
observed in the cytoplasm and nucleus, with no evident localization in
particular subcellular compartments; however, the rare cells in
metaphase showed a peculiar distribution of anti-ERK1 staining (Fig. 7,
third row, right panel). Indeed, a higher level of ERK1
immunopositivity was associated with the microtubules of the meiotic
spindle, as demonstrated by the double staining with anti-
-tubulin
antibody (Fig. 7, third row, middle panel). On the other
hand, anti-ERK1 and anti-tubulin staining was negative where the
condensed chromosomes are localized. In OA-treated cells, in which
formation of the meiotic spindle is impaired (34) and the chromosomes
condense to form a ring structure, both anti-tubulin and anti-ERK1
stainings maintain a diffuse distribution, whereas they are absent in
the area were the condensed chromatin is found (Fig. 7, fourth
row, middle and right panels). Considering the degree
of ERK2 cross-reactivity (see Fig. 2) of the anti-ERK1 antibody used
for immunofluorescence experiments, we cannot rule out that the
subcellular localization seen for ERK1 reflects, at least in part, also
the localization of ERK2. This result shows that ERKs concentrate in
the meiotic spindles during physiological G2/M transition
in mouse spermatocytes.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 7.
Subcellular redistribution of ERKs in mouse
spermatocytes during the G2/M transition. Fluorescence
microphotographs of untreated (first, second, and
third row) and OA-treated (fourth row) mouse
spermatocytes subjected to double indirect immunofluorescence analysis
with mouse monoclonal anti- -tubulin (middle panels) and
rabbit polyclonal anti-ERK1 (right panels) antibodies, or to
immunofluorescence analysis with non-immune mouse or rabbit IgGs as a
control. All samples were also stained with Hoechst for the
visualization of chromatin (left panels). Magnification: × 1050.
|
|
OA-activated ERK1 Induces MPF Activity in Mouse Spermatocyte Cell
Extracts--
It has been reported that in Xenopus oocytes
activation of ERK2 is required for Mos-dependent activation
of MPF (8). We investigated whether ERK1, which appears to be
specifically activated during the OA-induced G2/M
transition in mouse spermatocytes, is able to play a similar role. To
test this hypothesis, we immunoprecipitated cell extracts from
spermatocytes incubated for 4 h in the absence or presence of 5 µM OA with either the anti-ERK1 or anti-ERK2 antibody.
The immunoprecipitated ERKs were incubated for 30 min with a cytosolic
extract from untreated spermatocytes to test the eventual ability of
the immunoprecipitated ERKs to activate endogenous MPF in these
extracts. After separation from the immunoprecipitates, H1 kinase
activity was measured in the cell extracts. As shown in Fig.
8, a 2-fold increase in H1 kinase
activity was measured in cytosolic extracts incubated with anti-ERK1
immunoprecipitates from OA-treated cells as compared with anti-ERK1
immunoprecipitates from control cells. ERK2 immunoprecipitated from
OA-treated cells was not able to induce such an increase. These data
show that, following OA treatment, ERK1, but not ERK2, is able to
trigger MPF activation in cytosolic extracts of unstimulated
spermatocytes.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 8.
OA-activated ERK1 induces MPF activity in
mouse spermatocyte cell extracts. ERKs were imunoprecipitated from
control spermatocytes or spermatocytes treated with 5 µM
OA for 4 h using either anti-ERK1 or anti-ERK2 antibodies.
Immunocomplexes were washed thoroughly and 200 µg of cytosolic
extracts from untreated pachytene spermatocytes were added and
incubated with the immunocomplexes for 30 min at 30 °C under
constant shaking. After separation by centrifugation, an H1 kinase
assay was performed on the soluble cell extracts that had been
incubated with either anti-ERK1 or anti-ERK2 immunoprecipitates from
control and OA-treated cells (see "Materials and Methods" for
details). Data represent the mean ± S.D. of triplicate
determinations from three separate experiments.
|
|
Inhibition of ERK Activating Kinases (MEKs) Prevents OA-induced
Chromosome Condensation--
In order to establish the contribution of
the MAPK/ERK pathway in chromosome condensation during OA-induced
meiotic male G2/M transition, we preincubated cultured
mouse spermatocytes with the specific MEK1/2 inhibitor PD98059 (35),
which was predicted to impair selectively ERK activation by OA. We
found that treatment with 0.5 µM OA, instead than 5 µM, was sufficient to induce nuclear envelope breakdown
and chromosome condensation typical of G2/M transition
(Fig. 9A). Overnight
preincubation with 50 µM PD98059 completely blocked the
massive induction of metaphase by subsequent treatment with 0.5 µM OA (Fig. 9A). Under these conditions,
PD98059 inhibited OA-induced ERK1 activation, as measured by MBP
phosphorylation by anti-ERK1 immunoprecipitates (Fig. 9B).
Interestingly, PD98059 pretreatment did not affect OA-induced MPF
activation, measured through phosphorylation of H1 by either total
spermatocyte cell extracts or anti-cyclin B1 immunoprecipitates (data
not shown). Thus, ERK1 induction by OA is essential for chromosome
condensation in spermatocytes undergoing the first meiotic division,
independently from its ability to participate in MPF activation.

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 9.
Preincubation with the MEK1/2 inhibitor
PD98059 prevents the ability of OA to trigger ERK1 activation and
chromosome condensation associated with meiotic progression in mouse
spermatocytes. A, Giemsa staining of nuclei from control
spermatocytes preincubated for 12 h with or without 50 µM PD98059, and subsequently treated for 5 h with or
without 0.5 µM OA. All panels show spermatocyte nuclei
with different degrees of chromosome condensation, with the exception a
Sertoli cell nucleus in the second panel (indicated by an
asterisk). Magnification: × 160. B,
phosphorylation of the full-length MBP protein by anti-ERK1
immunoprecipitates from control spermatocytes preincubated for 12 h with or without 50 µM PD98059, and subsequently treated
for 5 h with or without 5 µM or 0.5 µM
OA. After immunoprecipitation of ERK1, a kinase assay was performed
using the full-length MBP protein as a substrate, and the soluble
fraction was analyzed by SDS-PAGE and autoradiography.
|
|
 |
DISCUSSION |
The present data, in addition to confirming that the increase in
H1 kinase activity previously observed in the OA-induced G2/M transition in mouse pachytene spermatocytes (22, 23) is actually due to activation of MPF (the cyclin B1·cdc2 complex), also demonstrate that the OA-induced G2/M transition is
associated with an increase in MAPK activity, with a timing parallel to
that of MPF activation and to that of chromosome condensation. The increase of MAPK activity is due to selective activation of the ERK1
isoform, and it is associated with increased phosphorylation of a
tyrosine residue involved in enzyme activation. MPF activation might be
directly responsible for the further chromosome condensation observed
during the OA-induced G2/M meiotic transition. Indeed, it
has been recently shown that cdc2 can phosphorylate and activate the 13 S condensin multisubunit protein complex which is essential for mitotic
chromosome condensation (36). However, studies in mouse oocytes also
suggest that MAPKs can play a direct role in chromosome condensation
independently from the state of MPF activity (19, 32). Indeed we found
that blocking OA-induced ERK1 activation through preincubation of
spermatocytes with PD98059, a selective inhibitor of ERK-activating
MEK1/2 kinases, is able to prevent the formation of metaphase
chromosomes. Since this treatment did not block OA-induced MPF
activation, it can be concluded that activation of ERK1, rather than of
MPF, is strictly required for chromosome condensation during male
meiotic methaphase I.
We also observed that the natural G2/M transition of
spermatocytes is associated to changes in the subcellular localization of ERKs, which reorganize from a diffuse cytoplasmic distribution in
pachytene spermatocytes to an apparent association with the meiotic
spindle in metaphase spermatocytes. The redistribution of ERKs at
metaphase appears to be dependent on spindle assembly, since in
OA-treated cells, where the spindle formation is impaired (34), ERKs
remain diffused in the cytoplasm.
The effects of OA on the cell cycle are thought to be mediated by
inhibition of serine-threonine phosphatase 2A (PP-2A) with the
consequent activation of the cdc2 kinase (37). The observation that
purified PP-2A dephosphorylates in vitro activating residues of cdc2 kinase, such as Thr161, would suggest a direct
regulation of MPF activity by PP-2A (38, 39), whereas experiments
performed with Xenopus egg extracts indicate that PP-2A acts
by inhibiting the activity of the dual specificity phosphatase cdc25
(40). Dephosphorylation of Thr14 and Tyr15 of
cdc2 by cdc25 results in activation of MPF (12). This mechanism could
be part of a positive feedback, since activated MPF is able to
phosphorylate and activate cdc25 (41, 42). In addition to cdc2, other
protein kinases are able to phosphorylate and regulate cdc25 (43). For
instance, it has been shown that cdc25 associates with Raf-1 in both
mammalian somatic cells and frog meiotic oocytes, and it can be
activated in vitro in a Raf-1-dependent manner
(44). Raf-1 is a well known upstream activator of ERK1/ERK2 and it is present in mouse spermatocytes
(45).2 We now show that
OA-activated ERK1 is able to induce activation of MPF in spermatocyte
cell extracts, suggesting that OA might regulate MPF activity by
downstream activation of multiple Raf-dependent pathways
(cdc25 and/or ERK1), and that the Ras/Raf pathway might be functional
in male meiotic cells.
PP-2A has been reported to dephosphorylate critical threonine residues
of MAPKs required for enzyme activation (46-48), and OA stimulates
MAPK activity in several cell systems (8, 49). In agreement with a
direct role of PP-2A on both MPF and MAPK regulation, we found that OA
treatment induced a concomitant increase of MPF and MAPK activity in
mouse spermatocytes. Furthermore, inhibition of OA-induced ERK1
activation by preincubation of mouse spermatocytes with PD98059 did not
prevent MPF activation, confirming that activation of cdc25 by OA is
sufficient to trigger activation of the cyclin B·cdc2 complex during
the male meiotic G2/M transition. Thus, our data suggest
that OA overcomes the physiological regulation of the cell cycle events
in spermatocytes by inhibiting PP-2A activity. However, since
activation of ERK1 leads to activation of MPF in spematocyte cell
extracts, it is conceivable that a differential temporal activation of
ERK1 and MPF occurs during physiological meiotic progression in these
cells. Furthermore, we report here that OA induces a 5-fold increase in
MPF activity in the absence of serum, whereas the increase in H1 kinase
activity in spermatocytes cultured in the presence of serum varies
between 2- and 4-fold (22, 23). Although these differences could be simply due to culture conditions, it is also possible that growth factors present in serum are able to trigger partial activation of
MAPKs (and consequently of MPF), lowering the apparent effect of OA. In
agreement with this hypothesis, we observed that MAPK activity was
higher in spermatocytes cultured in the presence of serum, and that
OA-induced MAPK activation was less evident under these
conditions.2
In Xenopus oocytes, Mos-dependent activation of
MPF requires ERK2 (8, 10), whereas we found that OA selectively
activates ERK1, but not ERK2, during meiotic progression of primary
spermatocytes. This is a further example of dimorphism in the
regulation of cell cycle events between male and female meiosis in
mammals (1). Activated ERK1 immunoprecipitated from OA-treated
spermatocytes can activate H1 kinase activity in extracts from control
pachytene spermatocytes. Since we found that the increase in H1 kinase
activity induced by OA measured in the spermatocyte cell extracts
corresponds to that immunoprecipitated by the anti-cyclin B1 antibody,
these results indicate that ERK1 might be directly involved in MPF
activation in these cells. Recently, it has been shown that MAPKs, via
activation of p90rsk kinase (50) and the consequent
inactivation of the cdc2 inhibitory kinase Myt1, can regulate MPF
activity in Xenopus oocytes (16). It is, therefore, possible
that similar mechanisms are also functional in male meiosis.
MPF is also a major target of endogenous checkpoints controlling the
timing of meiotic events (1). Genomic integrity is a prerequisite for
the progression of the cell cycle, as shown by targeted disruption of
genes involved in DNA mismatch repair, such as Pms2 (51) and Mlh1
(52-53), or in DNA recombination, such as Dmc1 (54, 55), which leads
to a meiotic arrest resulting in sterility in male and female mice. A
possible link between the DNA damage checkpoint and the progression of
the meiotic cell cycle is represented by serine-threonine kinases such
as ATM and chk1. Targeted disruption of ATM, a phosphatidylinositol
3-kinase-related protein kinase homologous to the yeast DNA-damage
checkpoint protein Rad3 (56), causes mouse infertility due to meiotic
arrest (57-60) in the early prophase I (61). A protein kinase that
acts downstream to ATM is chk1, which is associated with meiotic
chromosomes in mouse pachytene spermatocytes (62) and has been shown to
phosphorylate and indirectly inhibit the cdc25 in yeast and mammalian
mitotic cells (63-65). MPF activity and meiotic progression in
spermatocytes is also regulated by temporal expression of germ
cell-specific genes (66). For instance, HSP70-2, a heat-shock protein
specifically expressed in pachytene spermatocytes and associated with
synaptonemal complexes, seems to function as a molecular chaperone
required for the assembly of cyclin B1·cdc2 complex formation and
activity in pachytene spermatocytes (67). Mice carrying targeted
disruption of HSP70-2 display a spermatogenic block in late prophase I,
due to failure of chromosomes to desynapse (68, 69). A similar phenotype, i.e. arrest in late prophase I coupled to low
cyclin B1·cdc2 kinase activity, was also observed in mice carrying
targeted disruption of another spermatocyte-specific gene, cyclin A1
(70).
Activation of ERK1 during OA-induced meiotic progression, its
association with the metaphase spindle, its ability to activate MPF in
extracts from mouse spermatocytes, and the observation that it is
required for OA-induced chromosome condensation at metaphase
(independently from its ability to induce MPF activation) indicate that
ERK1 might play a role in the G2/M transition in male
meiosis. It is known that ERK1 is activated by extracellular signals
(24), and this might imply that the environment surrounding spermatocytes within the seminiferous epithelium acts in concert with
intracellular mechanisms to regulate the ordered progression of male
meiosis through prophase I.